Upregulation of Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 Expres Sion Contributed to the Vein Graft Atherosclerosis: Modulation by Losartan

黄东,葛均波,梁春,罗育坤,贾庆哲,王克强
DOI: https://doi.org/10.3760/j:issn:0253-3758.2004.10.016
2004-01-01
Abstract:Objective To study the expression of lectin-like oxidized low density lipoprotein recepto r-1 (LOX-1) in the autologous rabbit vein graft and the modulating anti-ather osclerotic effect of losartan (a specific type 1 angiotensin II receptor antagon ist). Methods Autologous external jugular veins were grafted to common carotid arteries in 30 male New Zealand white rabbits. After surgery, rabbits were randomly assinged into 3 groups (10 rabbits in each): (1) HC group (fed with high cholesterol diet); (2) LHC group (fed with high cholesterol diet puls losartan of 10 mg·kg_-1·d_-1); (3) control group (fed with reg ular chow). All the animals were sacrificed at the end of 12th week. Serum lipi d levels were measured and vein grafts intimal thickening was quantitated in HE stained segments. LOX-1 mRNA expressions in the grafts were examined by immunoh istochemistry and semi-quantitative reverse transcription-PCR. Result s Neointimal hyperplasia was observed in all vein grafts characterized by extensive intimal thickening. Typical atherosclerotic lesions were found in vein grafts of HC group which were attenuated by losartan. Losartan also reduc ed the size of the lesion and lessened the vulnerability of the atherosclerotic plaque of vein grafts. A modest LOX-1 expression was shown in the endothelium a nd neointima of vein grafts in the control group. LOX-1 expression was signifi cantly upregulated in the endothelium and atherosclerotic lesions in HC group(0 .93±0.34 vs. 0.31±0.14,P0.01), and losartan downregulated the LOX -1 expression caused by high lipidemia (0.52±0.21 vs. 0.93±0.34,P0 .01). Conclusion LOX-1 is expressed in endothelium and neoi ntima of autologous vein graft of rabbits. Hypercholesterolemia upregulates LOX -1 expression in vein graft atherosclerosis. Losartan could attenuate the vein graft atherosclerosis through the downregulation of LOX-1 expression.
What problem does this paper attempt to address?